Skip to main content
Top
Published in: BMC Cancer 1/2009

Open Access 01-12-2009 | Research article

Population based prostate cancer screening in north Mexico reveals a high prevalence of aggressive tumors in detected cases

Authors: Lauro S Gomez-Guerra, Margarita L Martinez-Fierro, Valeria Alcantara-Aragon, Rocio Ortiz-Lopez, Rebeca T Martinez-Villarreal, Idelma B Morales-Rodriguez, Raquel Garza-Guajardo, Marco A Ponce-Camacho, Augusto Rojas-Martinez

Published in: BMC Cancer | Issue 1/2009

Login to get access

Abstract

Background

Prostate Cancer (PCa) is the second most frequent neoplasia in men worldwide. Previous reports suggest that the prevalence of PCa in Hispanic males is lower than in Africans (including communities with African ancestry) and Caucasians, but higher than in Asians. Despite these antecedents, there are few reports of open population screenings for PCa in Latin American communities. This article describes the results of three consecutive screenings in the urban population of Monterrey, Mexico.

Methods

After receiving approval from our University Hospital's Internal Review Board (IRB), the screening was announced by radio, television, and press, and it was addressed to male subjects over 40 years old in general. Subjects who consented to participate were evaluated at the primary care clinics of the University Health Program at UANL, in the Metropolitan area of Monterrey. Blood samples were taken from each subject for prostate specific antigen (PSA) determination; they underwent a digital rectal examination (DRE), and were subsequently interviewed to obtain demographic and urologic data. Based on the PSA (>4.0 ng/ml) and DRE results, subjects were appointed for transrectal biopsy (TRB).

Results

A total of 973 subjects were screened. Prostate biopsy was recommended to 125 men based on PSA values and DRE results, but it was performed in only 55 of them. 15 of these biopsied men were diagnosed with PCa, mostly with Gleason scores ≥ 7.

Conclusion

Our results reflect a low prevalence of PCa in general, but a high occurrence of high grade lesions (Gleason ≥ 7) among patients that resulted positive for PCa. This observation remarks the importance of the PCa screening programs in our Mexican community and the need for strict follow-up campaigns.
Appendix
Available only for authorised users
Literature
3.
go back to reference Harris R, Lohr KN: Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002, 137 (11): 917-929.CrossRefPubMed Harris R, Lohr KN: Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002, 137 (11): 917-929.CrossRefPubMed
4.
go back to reference Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS: Screening for prostate cancer. A decision analytic view. JAMA. 1994, 272 (10): 773-780. 10.1001/jama.272.10.773.CrossRefPubMed Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS: Screening for prostate cancer. A decision analytic view. JAMA. 1994, 272 (10): 773-780. 10.1001/jama.272.10.773.CrossRefPubMed
5.
go back to reference Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK: Prostate cancer screening: what we know and what we need to know. Ann Intern Med. 1993, 119 (9): 914-923.CrossRefPubMed Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK: Prostate cancer screening: what we know and what we need to know. Ann Intern Med. 1993, 119 (9): 914-923.CrossRefPubMed
7.
go back to reference Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008, 149 (3): 185-191. 2008/08/06 edition Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008, 149 (3): 185-191. 2008/08/06 edition
8.
go back to reference Hoedemaeker RF, Kwast van der TH, Boer R, de Koning HJ, Roobol M, Vis AN, Schroder FH: Pathologic features of prostate cancer found at population-based screening with a four-year interval. J Natl Cancer Inst. 2001, 93 (15): 1153-1158. 10.1093/jnci/93.15.1153.CrossRefPubMed Hoedemaeker RF, Kwast van der TH, Boer R, de Koning HJ, Roobol M, Vis AN, Schroder FH: Pathologic features of prostate cancer found at population-based screening with a four-year interval. J Natl Cancer Inst. 2001, 93 (15): 1153-1158. 10.1093/jnci/93.15.1153.CrossRefPubMed
9.
go back to reference Roobol MJ, Kranse R, de Koning HJ, Schroder FH: Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM). Urology. 2004, 63 (2): 309-313. 10.1016/j.urology.2003.09.083. discussion 313–305.CrossRefPubMed Roobol MJ, Kranse R, de Koning HJ, Schroder FH: Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM). Urology. 2004, 63 (2): 309-313. 10.1016/j.urology.2003.09.083. discussion 313–305.CrossRefPubMed
10.
go back to reference Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, et al: Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med. 2004, 350 (22): 2239-2246. 10.1056/NEJMoa031918.CrossRefPubMed Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, et al: Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med. 2004, 350 (22): 2239-2246. 10.1056/NEJMoa031918.CrossRefPubMed
11.
go back to reference Hedelin H, Johansson N, Stroberg P: Relationship between benign prostatic hyperplasia and lower urinary tract symptoms and correlation between prostate volume and serum prostate-specific antigen in clinical routine. Scand J Urol Nephrol. 2005, 39 (2): 154-159. 10.1080/00365590510007685.CrossRefPubMed Hedelin H, Johansson N, Stroberg P: Relationship between benign prostatic hyperplasia and lower urinary tract symptoms and correlation between prostate volume and serum prostate-specific antigen in clinical routine. Scand J Urol Nephrol. 2005, 39 (2): 154-159. 10.1080/00365590510007685.CrossRefPubMed
12.
go back to reference Simardi LH, Tobias-MacHado M, Kappaz GT, Taschner Goldenstein P, Potts JM, Wroclawski ER: Influence of asymptomatic histologic prostatitis on serum prostate-specific antigen: a prospective study. Urology. 2004, 64 (6): 1098-1101. 10.1016/j.urology.2004.08.060.CrossRefPubMed Simardi LH, Tobias-MacHado M, Kappaz GT, Taschner Goldenstein P, Potts JM, Wroclawski ER: Influence of asymptomatic histologic prostatitis on serum prostate-specific antigen: a prospective study. Urology. 2004, 64 (6): 1098-1101. 10.1016/j.urology.2004.08.060.CrossRefPubMed
13.
go back to reference Pannek J, Marks LS, Pearson JD, Rittenhouse HG, Chan DW, Shery ED, Gormley GJ, Subong EN, Kelley CA, Stoner E, et al: Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia. J Urol. 1998, 159 (2): 449-453. 10.1016/S0022-5347(01)63946-6.CrossRefPubMed Pannek J, Marks LS, Pearson JD, Rittenhouse HG, Chan DW, Shery ED, Gormley GJ, Subong EN, Kelley CA, Stoner E, et al: Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia. J Urol. 1998, 159 (2): 449-453. 10.1016/S0022-5347(01)63946-6.CrossRefPubMed
14.
go back to reference Eskew LA, Bare RL, McCullough DL: Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol. 1997, 157 (1): 199-202. 10.1016/S0022-5347(01)65322-9. discussion 202-193.CrossRefPubMed Eskew LA, Bare RL, McCullough DL: Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol. 1997, 157 (1): 199-202. 10.1016/S0022-5347(01)65322-9. discussion 202-193.CrossRefPubMed
15.
go back to reference Brossner C, Madersbacher S, Bayer G, Pycha A, Klingler HC, Maier U: Comparative study of two different TRUS-guided sextant biopsy techniques in detecting prostate cancer in one biopsy session. Eur Urol. 2000, 37 (1): 65-71. 10.1159/000020102.CrossRefPubMed Brossner C, Madersbacher S, Bayer G, Pycha A, Klingler HC, Maier U: Comparative study of two different TRUS-guided sextant biopsy techniques in detecting prostate cancer in one biopsy session. Eur Urol. 2000, 37 (1): 65-71. 10.1159/000020102.CrossRefPubMed
16.
go back to reference Stamatiou K, Alevizos A, Karanasiou V, Mariolis A, Mihas C, Papathanasiou M, Bovis K, Sofras F: Impact of additional sampling in the TRUS-guided biopsy for the diagnosis of prostate cancer. Urol Int. 2007, 78 (4): 313-317. 10.1159/000100834.CrossRefPubMed Stamatiou K, Alevizos A, Karanasiou V, Mariolis A, Mihas C, Papathanasiou M, Bovis K, Sofras F: Impact of additional sampling in the TRUS-guided biopsy for the diagnosis of prostate cancer. Urol Int. 2007, 78 (4): 313-317. 10.1159/000100834.CrossRefPubMed
Metadata
Title
Population based prostate cancer screening in north Mexico reveals a high prevalence of aggressive tumors in detected cases
Authors
Lauro S Gomez-Guerra
Margarita L Martinez-Fierro
Valeria Alcantara-Aragon
Rocio Ortiz-Lopez
Rebeca T Martinez-Villarreal
Idelma B Morales-Rodriguez
Raquel Garza-Guajardo
Marco A Ponce-Camacho
Augusto Rojas-Martinez
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2009
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-9-91

Other articles of this Issue 1/2009

BMC Cancer 1/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine